FTS and 2-DG induce pancreatic cancer cell death and tumor shrinkage in mice

Cell Death and Disease

Volumn 3, Issue 3, 2012, Pages

  Goldberg, L ^a   Israeli, R ^a   Kloog, Y ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

2 DG; FTS; Pancreatic cancer; Ras; Ras oncogenes

Indexed keywords

CASPASE 3; DEOXYGLUCOSE; SALIRASIB; SURVIVIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL DEATH; CELL PROLIFERATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO CULTURE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL PROLIFERATION; DEOXYGLUCOSE; DRUG SYNERGISM; FARNESOL; GLYCOLYSIS; HUMANS; MICE; MICE, NUDE; ORGAN SIZE; PANCREAS; PANCREATIC NEOPLASMS; SALICYLIC ACIDS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84859363762     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.24     Document Type: Article

References (39)

1. Cox AD, Der CJ. Ras history: the saga continues. Small Gtpases 2011; 1: 2-27.
2. Downward J. Ras signalling and apoptosis. Curr Opin Genet Dev 1998; 8: 49-54. (Pubitemid 28122140)
3. Joneson T, White MA, Wigler MH, Bar Sagi D. Stimulation of membrane ruffling and MAP kinase activation by distinct effectors of RAS. Science 1996; 271: 810-812. (Pubitemid 26060736)
4. Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ. Increasing complexity of Ras signaling. Oncogene 1998; 17 (11 Reviews): 1395-1413.
5. McCormick F. Signal transduction. How receptors turn Ras on. Nature 1993; 363: 15-16.
6. Boguski MS, McCormick F. Proteins regulating Ras and its relatives. Nature 1993; 366: 643-654. (Pubitemid 24036012)
7. Scheffzek K, Ahmadian MR, Kabsch W, Wiesmuller L, Lautwein A, Schmitz F et al. The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 1997; 277: 333-338. (Pubitemid 27450699)
8. Wittinghofer A, Vetter IR. Structure-function relationships of the G domain, a canonical switch motif. Annu Rev Biochem 2011; 80: 943-971.
9. Egan SE, Giddings BW, Brooks MW, Buday L, Sizeland AM, Weinberg RA. Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation. Nature 1993; 363: 45-51. (Pubitemid 23144959)
10. Gale NW, Kaplan S, Lowenstein EJ, Schlessinger J, Bar-Sagi D. Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on Ras. Nature 1993; 363: 88-92. (Pubitemid 23144969)
11. Boyartchuk VL, Ashby MN, Rine J. Modulation of Ras and a-factor function by carboxylterminal proteolysis. Science 1997; 275: 1796-1800. (Pubitemid 27136718)
12. Hancock JF, Cadwallader K, Marshall CJ. Methylation and proteolysis are essential for efficient membrane binding of prenylated p21K-ras(B). EMBO J 1991; 10: 641-646. (Pubitemid 21905518)
13. Shoji H, Deltour L, Nakamura T, Tajbakhsh S, Poirier F. Expression pattern and role of Galectin1 during early mouse myogenesis. Dev Growth Differ 2009; 51: 607-615.
14. Elad-Sfadia G, Haklai R, Balan E, Kloog Y. Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity. J Biol Chem 2004; 279: 34922-34930. (Pubitemid 39318128)
15. Elad-Sfadia G, Haklai R, Ballan E, Gabius HJ, Kloog Y. Galectin-1 augments Ras activation and diverts Ras signals to Raf-1 at the expense of phosphoinositide 3-kinase. J Biol Chem 2002; 277: 37169-37175.
16. Shalom-Feuerstein R, Cooks T, Raz A, Kloog Y. Galectin-3 regulates a molecular switch from N-Ras to K-Ras usage in human breast carcinoma cells. Cancer Res 2005; 65: 7292-7300. (Pubitemid 41161261)
17. Rotblat B, Niv H, Andre S, Kaltner H, Gabius HJ, Kloog Y. Galectin-1(L11A) predicted from a computed galectin-1 farnesyl-binding pocket selectively inhibits Ras-GTP. Cancer Res 2004; 64: 3112-3118. (Pubitemid 38581411)
18. Rotblat B, Belanis L, Liang H, Haklai R, Elad-Zefadia G, Hancock JF et al. H-Ras nanocluster stability regulates the magnitude of MAPK signal output. PLoS One 2010; 5: e11991.
19. Shalom-Feuerstein R, Plowman SJ, Rotblat B, Ariotti N, Tian T, Hancock JF et al. K-ras nanoclustering is subverted by overexpression of the scaffold protein galectin-3. Cancer Res 2008; 68: 6608-6616.
20. Farin K, Schokoroy S, Haklai R, Cohen-Or I, Elad-Sfadia G, Reyes-Reyes ME et al. Oncogenic synergism between ErbB1, nucleolin, and mutant Ras. Cancer Res 2011; 71: 2140-2151.
21. Haklai R, Gana-Weisz G, Elad G, Paz A, Marciano D, Egozi Y et al. Dislodgment and accelerated degradation of Ras. Biochemistry 1998; 37: 1306-1314.
22. Elad G, Paz A, Haklai R, Marciano D, Cox A, Kloog Y. Targeting of K-Ras 4B by S-trans, trans-farnesyl thiosalicylic acid. Biochim Biophys Acta 1999; 1452: 228-242.
23. Goldberg L, Ocherashvilli A, Daniels D, Last D, Cohen ZR, Tamar G et al. Salirasib (farnesyl thiosalicylic acid) for brain tumor treatment: a convection-enhanced drug delivery study in rats. Mol Cancer Ther 2008; 7: 3609-3616.
24. Haklai R, Elad-Sfadia G, Egozi Y, Kloog Y. Orally administered FTS (Salirasib) inhibits human pancreatic tumor growth in nude mice. Cancer Chemother Pharmacol 2008; 61: 89-96. (Pubitemid 47512630)
25. Levy R, Grafi-Cohen M, Kraiem Z, Kloog Y. Galectin-3 promotes chronic activation of KRas and differentiation block in malignant thyroid carcinomas. Mol Cancer Ther 2011; 9: 2208-2219.
26. Weisz B, Giehl K, Gana-Weisz M, Egozi Y, Ben-Baruch G, Marciano D et al. A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice. Oncogene 1999; 18: 2579-2588. (Pubitemid 29216680)
27. Blum R, Jacob-Hirsch J, Amariglio N, Rechavi G, Kloog Y. Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. Cancer Res 2005; 65: 999-1006. (Pubitemid 40216462)
28. Dearling JL, Flynn AA, Sutcliffe-Goulden J, Petrie IA, Boden R, Green AJ et al. Analysis of the regional uptake of radiolabeled deoxyglucose analogs in human tumor xenografts. J Nucl Med 2004; 45: 101-107. (Pubitemid 47611615)
29. Maher JC, Krishan A, Lampidis TJ. Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic versus aerobic conditions. Cancer Chemother Pharmacol 2004; 53: 116-122. (Pubitemid 38186989)
30. Aft RL, Lewis JS, Zhang F, Kim J, Welch MJ. Enhancing targeted radiotherapy by copper(II)diacetyl- bis(N4-methylthiosemicarbazone) using 2-deoxy-D-glucose. Cancer Res 2003; 63: 5496-5504. (Pubitemid 37139869)
31. Coleman MC, Asbury CR, Daniels D, Du J, Aykin-Burns N, Smith BJ et al. 2-deoxy-Dglucose causes cytotoxicity, oxidative stress, and radiosensitization in pancreatic cancer. Free Radic Biol Med 2008; 44: 322-331.
32. Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF et al. 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 2004; 64: 31-34. (Pubitemid 38114078)
33. Aft RL, Zhang FW, Gius D. Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell death. Br J Cancer 2002; 87: 805-812. (Pubitemid 35178760)
34. Gupta S, Mathur R, Dwarakanath BS. The glycolytic inhibitor 2-deoxy-D-glucose enhances the efficacy of etoposide in ehrlich ascites tumor-bearing mice. Cancer Biol Ther 2005; 4: 87-94. (Pubitemid 41350937)
35. Chifenti B, Morelli M, Zavaglia M, Coviello DA, Guerneri S, Santucci A et al. Establishment and characterization of 4 new human pancreatic cancer cell lines: evidences of different tumor phenotypes. Pancreas 2009; 38: 184-196.
36. Colak A, Antar V, Karaoglan A, Akdemir O, Sahan E, Celik O et al. Q-VD-OPh, a pancaspase inhibitor, reduces trauma-induced apoptosis and improves the recovery of hind-limb function in rats after spinal cord injury. Neurocirugia (Astur) 2009; 20: 533-540 discussion 540.
37. Blum R, Jacob-Hirsch J, Rechavi G, Kloog Y. Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosis. Mol Cancer Ther 2006; 5: 2337-2347. (Pubitemid 44530471)
38. Blum R, Elkon R, Yaari S, Zundelevich A, Jacob-Hirsch J, Rechavi G et al. Gene expression signature of human cancer cell lines treated with the Ras inhibitor salirasib (S-farnesylthiosalicylic acid). Cancer Res 2007; 67: 3320-3328. (Pubitemid 46724871)
39. Ramirez-Peinado S, Alcazar-Limones F, Lagares-Tena L, El Mjiyad N, Caro-Maldonado A, Tirado OM et al. 2-deoxyglucose induces Noxa-dependent apoptosis in alveolar rhabdomyosarcoma. Cancer Res 2011; 71: 6796-6806.